Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection

World Journal of Gastroenterology

Volumn 18, Issue 18, 2012, Pages 2225-2230

  Mori, Naoki ^a   Nakasone, Kazunori ^b   Tomimori, Koh ^a,c   Ishikawa, Chie ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Nakasonekazu Medical Clinic   (Japan)

^c Naha City Hospital   (Japan)

Author keywords

Fucoidan; Hepatitis C virus; Replicon

Indexed keywords

ALANINE AMINOTRANSFERASE; FUCOIDIN; ANTIVIRUS AGENT; POLYSACCHARIDE; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMED CONSENT; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NONHUMAN; OPEN STUDY; REPLICON; VERY ELDERLY; VIRUS EXPRESSION; VIRUS REPLICATION; BLOOD; DOSE RESPONSE; DRUG EFFECT; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; JAPAN; LIVER TUMOR; PILOT STUDY; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; JAPAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYSACCHARIDES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84866258676     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i18.2225     Document Type: Article

References (26)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115
3. Gao X, Cui Q, Shi X, Su J, Peng Z, Chen X, Lei N, Ding K, Wang L, Yu R, Wang N. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis 2011; 11: 88
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
5. Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C-an updated Cochrane review. Aliment Pharmacol Ther 2010; 32: 840-850
6. Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15: 2-11
7. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002; 4: 23-30
8. Vermehren J, Sarrazin C. New hepatitis C therapies in clinical development. Eur J Med Res 2011; 16: 303-314
9. Siddiqui U, Weinshel EH, Bini EJ. Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38: 605-610
10. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA 2010; 107: 5995-5999
11. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47: 605-612
12. Kaji K, Yoshida S, Nagata N, Yamashita T, Mizukoshi E, Honda M, Kojima Y, Kaneko S. An open-label study of administration of EH0202, a health-food additive, to patients with chronic hepatitis C. J Gastroenterol 2004; 39: 873-878
13. Shikov AN, Djachuk GI, Sergeev DV, Pozharitskaya ON, Esaulenko EV, Kosman VM, Makarov VG. Birch bark extract as therapy for chronic hepatitis C - a pilot study. Phytomedicine 2011; 18: 807-810
14. Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology 2003; 13: 29R-40R
15. Park HY, Han MH, Park C, Jin CY, Kim GY, Choi IW, Kim ND, Nam TJ, Kwon TK, Choi YH. Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol 2011; 49: 1745-1752
16. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988; 32: 1742-1745
17. Hidari KI, Takahashi N, Arihara M, Nagaoka M, Morita K, Suzuki T. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem Biophys Res Commun 2008; 376: 91-95
18. Taoda N, Shinji E, Nishii K, Nishioka S, Yonezawa Y, Uematsu J, Hattori E, Yamamoto H, Kawano M, Tsurudome M, O'Brien M, Yamashita T, Komada H. Fucoidan inhibits parainfluenza virus type 2 infection to LLCMK2 cells. Biomed Res 2008; 29: 331-334
19. Araya N, Takahashi K, Sato T, Nakamura T, Sawa C, Hasegawa D, Ando H, Aratani S, Yagishita N, Fujii R, Oka H, Nishioka K, Nakajima T, Mori N, Yamano Y. Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease. Antivir Ther 2011; 16: 89-98
20. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, Tsukuda T, Shimma N, Aoki Y, Arisawa M, Kohara M, Sudoh M. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 2005; 1: 333-337
21. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863
22. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007; 353: 882-888
23. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62 Suppl 1: 8-17
24. Hayashi K, Nakano T, Hashimoto M, Kanekiyo K, Hayashi T. Defensive effects of a fucoidan from brown alga Undaria pinnatifida against herpes simplex virus infection. Int Immunopharmacol 2008; 8: 109-116
25. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamous JP, Erlinger S. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056
26. Chevaliez S, Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35 Suppl 1: S31-S41